Table 2.
Treatment and outcome of four HIV-infected patients
| Parameters | Case 1 | Case 2 | Case 3 | Case 4 |
|---|---|---|---|---|
| ART regimens | TDF + 3TC + DTG | TDF + 3TC + DTG | TDF + 3TC + DTG | TDF + 3TC + EFV/DTG |
| IVIG course (times) | 1 | 0 | 0 | 2 |
| RBCT (unit) | 13 | 5 | 2 | 6 |
| Hb (g/L) | 143 | 110 | 109 | 166 |
| B19V DNA | − | − | − | − |
| B19V IgM | N/A | − | − | − |
| B19V IgG | N/A | + | + | + |
| CD4 (cells/μL) | 162 | 233 | 142 | 145 |
| HIV RNA (copies/mL) | <20 | <20 | <20 | <20 |
| Recover period (mo) | 3.5 | 3.0 | 3.0 | 7.0 |
−: Negative; +: Positive; 3TC: Lamivudine; ART: Antiretroviral therapy; B19V: Parvovirus B19 virus; CD4: CD4 T-cell; DTG: Dolutegravir; EFV: Efavirenz; Hb: Hemoglobin; HIV: Human immunodeficiency virus; IVIG: Intravenous immunoglobulin; N/A: Not available; RBCT: Red blood cell transfusion; TDF: Tenofovir disoproxil.